1Y Target$18.06Near-term target
5Y Target$33.49Compound horizon
10Y Target$87.14Long-dated conviction
FCF$1.7bTTM · 03/26C+FCF $1.7b — respectable but not differentiating · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+8.1%TTM YoYBRevenue +8.1% — at or above S&P median
D/E1.00BD/E 1.00 — at market average, manageable
P/S1.3xA-P/S 1.3x — cheap for any tech/growth name
PEG0.15APEG 0.15 — exceptional; paying well under fair value for growth
Why now
Drug Manufacturers - Specialty & Generic · market cap $19.4b. 5% off the 52-week high of $17.53. PEG 0.15 — paying under fair value for the growth rate. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $18.06 (implying +8% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -2.0%) — path to GAAP profitability is the core thesis risk. ROE -2% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. Patent cliff exposure — a single approved molecule can carry the company; when patent protection expires, generic / biosimilar competition can erase 80% of the revenue in 2-3 years.
Horizon
1-3 yr $18.06 (9-analyst consensus) — catalyst-driven; binary events dominate. 5 yr $33.49 — requires the platform / technology to reach commercial scale. 10 yr $87.14 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.